Krystal Biotech, Inc. Forecast, price target & analysts
Krystal Biotech, Inc. Target price 2025 - Analyst rating & recommendation
Krystal Biotech, Inc. Classifications & Recommendation:
Krystal Biotech, Inc. Price Target
| Target Price | $211.44 |
| Price | $173.35 |
| Potential |
21.98%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Krystal Biotech, Inc. 2026 .
The average Krystal Biotech, Inc. target price is $211.44.
This is
21.98%
register free of charge
$221.00
27.49%
register free of charge
$195.00
12.49%
register free of charge
|
|
| A rating was issued by 10 analysts: 9 Analysts recommend Krystal Biotech, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Krystal Biotech, Inc. stock has an average upside potential 2026 of
21.98%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 290.52 | 461.29 |
| 473.02% | 58.78% | |
| EBITDA Margin | 37.84% | 48.54% |
| 120.80% | 28.27% | |
| Net Margin | 29.73% | 45.72% |
| 34.24% | 53.79% |
9 Analysts have issued a sales forecast Krystal Biotech, Inc. 2025 . The average Krystal Biotech, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Krystal Biotech, Inc. EBITDA forecast 2025. The average Krystal Biotech, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Krystal Biotech, Inc. Analysts have issued a net profit forecast 2025. The average Krystal Biotech, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 3.00 | 7.33 |
| 669.23% | 144.33% | |
| P/E | 23.67 | |
| EV/Sales | 9.55 |
2 Analysts have issued a Krystal Biotech, Inc. forecast for earnings per share. The average Krystal Biotech, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Krystal Biotech, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Krystal Biotech, Inc....
Current Krystal Biotech, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Feb 20 2025 |
| Chardan Capital | Locked ➜ Locked | Locked | Feb 20 2025 |
| Citigroup | Locked ➜ Locked | Locked | Feb 20 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 19 2025 |
| Chardan Capital | Locked ➜ Locked | Locked | Dec 18 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 18 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 13 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
Chardan Capital: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
Citigroup: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 19 2025 |
|
Locked
Chardan Capital: Locked ➜ Locked
|
Dec 18 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 18 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 13 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
